Hospital
Adventist Health System-Sunbelt INC
Adventist Health System-Sunbelt INC was paid $11.13M by Medicaid between Jan 2018 and Apr 2023, across 234 billing codes. Its largest line is 99283, emergency room visit (moderate) — 13% of everything it billed.
33Billing provider infoADVENTIST HEALTH SYSTEM-SUNBELT INC
WAUCHULA, FL 33873
WAUCHULA, FL 33873
33aNPI1457458986assigned 09/19/2006
33bProvider typeCritical Access Hospital
28Total paid$11.13M
24GClaims527,149
24DCodes billed234
24AFirst – last monthJan 2018 – Apr 2023
Compared with peers
Next to other Critical Access Hospital providers in Florida
Rank by total paid#1 of 12
Median peer was paid$3.14M
This provider vs. median3.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 55,328 | $509K | |
| 2019 | 114,341 | $2.23M | |
| 2020 | 103,750 | $2.02M | |
| 2021 | 122,742 | $2.95M | |
| 2022 | 110,684 | $2.81M | |
| 2023 | 20,304 | $612K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 22,148 | 19,886 | $1.50M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 10% | 18,982 | 16,298 | $1.16M |
| 96361 | Intravenous infusion, hydration; each additional hour | 4.8% | 7,560 | 6,481 | $538K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.8% | 9,179 | 7,558 | $531K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 4.2% | 5,843 | 4,980 | $469K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.8% | 2,990 | 2,644 | $420K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 3.7% | 2,694 | 2,383 | $412K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.6% | 9,932 | 8,454 | $401K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.3% | 3,875 | 3,231 | $365K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3.1% | 17,892 | 11,047 | $341K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.9% | 4,478 | 4,087 | $320K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.5% | 8,253 | 6,752 | $281K |
222 more codes
| 80053 | Comprehensive metabolic panel | 2.5% | 27,074 | $280K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.0% | 1,992 | $223K |
| 59025 | Fetal non-stress test | 1.9% | 2,311 | $206K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.5% | 4,335 | $168K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.2% | 2,230 | $129K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 2,280 | $122K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.0% | 4,260 | $114K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,035 | $106K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,875 | $99K |
| G0378 | Hospital observation service, per hour | <1% | 5,902 | $96K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,031 | $91K |
| 36415 | Collection of venous blood by venipuncture | <1% | 15,908 | $90K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 2,755 | $89K |
| 01999 | <1% | 1,994 | $88K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 11,173 | $88K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,465 | $87K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,264 | $84K |
| 82947 | <1% | 7,480 | $83K | |
| 81025 | <1% | 6,265 | $78K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,815 | $76K |
| 81003 | <1% | 9,003 | $75K | |
| 71045 | Radiologic examination, chest; single view | <1% | 10,057 | $74K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,732 | $74K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,103 | $72K |
| 81001 | <1% | 13,685 | $71K | |
| 73630 | <1% | 1,289 | $65K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,532 | $64K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 1,375 | $59K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 517 | $56K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 313 | $56K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 34,904 | $52K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,460 | $51K |
| 73610 | <1% | 848 | $46K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 549 | $45K |
| 92587 | <1% | 987 | $40K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 217 | $40K |
| 73130 | <1% | 803 | $38K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,805 | $37K |
| 86850 | <1% | 1,549 | $36K | |
| 74018 | <1% | 1,332 | $36K | |
| 73564 | <1% | 1,116 | $31K | |
| 73110 | <1% | 568 | $30K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 13,189 | $27K |
| 86901 | <1% | 2,393 | $26K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 12,614 | $25K |
| 97162 | <1% | 261 | $24K | |
| C1769 | Guide wire | <1% | 1,553 | $23K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,105 | $23K |
| 93971 | <1% | 627 | $22K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,405 | $22K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 217 | $20K |
| 73030 | <1% | 979 | $20K | |
| 84112 | <1% | 261 | $20K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,384 | $19K |
| 76775 | <1% | 461 | $19K | |
| 72110 | <1% | 673 | $18K | |
| 76830 | Ultrasound, transvaginal | <1% | 500 | $17K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,630 | $16K |
| 80050 | General health panel | <1% | 500 | $15K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,858 | $15K |
| 87070 | <1% | 944 | $15K | |
| 84702 | <1% | 2,457 | $14K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 105 | $14K |
| 87081 | <1% | 1,675 | $14K | |
| 80061 | Lipid panel | <1% | 7,510 | $14K |
| 97161 | <1% | 182 | $12K | |
| 96376 | <1% | 1,852 | $12K | |
| 84484 | <1% | 9,312 | $12K | |
| 80076 | <1% | 910 | $12K | |
| 85610 | <1% | 5,580 | $12K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,681 | $11K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 82 | $11K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,644 | $10K |
| 85730 | <1% | 3,324 | $10K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,660 | $10K |
| 94060 | <1% | 124 | $9K | |
| 83880 | <1% | 3,078 | $9K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 40 | $8K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,010 | $8K |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 325 | $7K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,887 | $7K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 800 | $7K |
| 84439 | <1% | 3,590 | $7K | |
| 76536 | <1% | 126 | $7K | |
| 73502 | <1% | 301 | $7K | |
| 87420 | <1% | 539 | $7K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,924 | $7K |
| 82247 | <1% | 984 | $6K | |
| 12001 | <1% | 88 | $6K | |
| 86900 | <1% | 2,407 | $6K | |
| 87040 | <1% | 3,561 | $6K | |
| 85027 | <1% | 2,677 | $6K | |
| 84481 | <1% | 804 | $6K | |
| 84156 | <1% | 878 | $5K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 71 | $5K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,294 | $5K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,187 | $5K |
| 83690 | <1% | 5,751 | $5K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,109 | $5K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,328 | $5K |
| 83735 | <1% | 3,266 | $5K | |
| 83605 | <1% | 3,421 | $5K | |
| 93458 | <1% | 53 | $4K | |
| 88342 | <1% | 265 | $4K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,046 | $4K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 524 | $4K |
| 77080 | <1% | 272 | $4K | |
| 71250 | <1% | 151 | $4K | |
| 76642 | <1% | 89 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,337 | $3K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,460 | $3K |
| 72100 | <1% | 157 | $3K | |
| 86803 | <1% | 422 | $3K | |
| 86140 | <1% | 2,371 | $3K | |
| 82248 | <1% | 1,198 | $3K | |
| 85380 | <1% | 985 | $3K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 299 | $3K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,209 | $2K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 74 | $2K |
| 73080 | <1% | 56 | $2K | |
| 73562 | <1% | 70 | $2K | |
| 93880 | <1% | 136 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 39 | $2K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,562 | $2K |
| 84550 | <1% | 872 | $2K | |
| 84703 | <1% | 1,313 | $2K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,881 | $2K |
| 95806 | <1% | 25 | $2K | |
| 82607 | <1% | 1,962 | $2K | |
| 87077 | <1% | 2,645 | $2K | |
| 82570 | <1% | 1,809 | $2K | |
| 12011 | <1% | 39 | $2K | |
| 93970 | <1% | 48 | $2K | |
| 72050 | <1% | 64 | $2K | |
| 87186 | <1% | 3,466 | $1K | |
| 82077 | <1% | 529 | $1K | |
| 83540 | <1% | 908 | $1K | |
| 85651 | <1% | 1,504 | $1K | |
| 83970 | <1% | 158 | $1K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 40 | $1K |
| 87210 | <1% | 362 | $1K | |
| 73140 | <1% | 12 | $974.86 | |
| 82731 | <1% | 16 | $966.17 | |
| 82950 | <1% | 72 | $934.17 | |
| 71101 | <1% | 28 | $924.84 | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 16 | $888.26 |
| 82728 | <1% | 1,054 | $873.02 | |
| 92650 | <1% | 16 | $793.65 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,027 | $680.79 |
| 77066 | Tomosynthesis, mammo | <1% | 13 | $680.26 |
| 76641 | <1% | 23 | $675.50 | |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | <1% | 113 | $674.88 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,199 | $659.80 |
| 80074 | <1% | 55 | $639.67 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 293 | $638.46 |
| 82565 | <1% | 348 | $586.76 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 792 | $553.31 |
| 74022 | <1% | 125 | $521.73 | |
| J2704 | Injection, propofol, 10 mg | <1% | 171 | $506.16 |
| 51798 | <1% | 79 | $500.82 | |
| 73090 | <1% | 14 | $485.53 | |
| 72072 | <1% | 16 | $457.43 | |
| 90715 | <1% | 391 | $456.79 | |
| 84999 | <1% | 76 | $451.04 | |
| 76801 | <1% | 54 | $433.96 | |
| 86780 | <1% | 511 | $431.22 | |
| 94729 | <1% | 83 | $430.83 | |
| 82272 | <1% | 158 | $414.35 | |
| 82043 | <1% | 1,073 | $393.24 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 1,511 | $330.66 |
| 70360 | <1% | 13 | $330.61 | |
| 82746 | <1% | 856 | $316.10 | |
| 82550 | <1% | 248 | $259.94 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 655 | $255.97 |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 14 | $227.88 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 92 | $227.36 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 107 | $214.82 |
| 84520 | <1% | 189 | $191.66 | |
| 94726 | <1% | 100 | $176.33 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 70 | $154.65 |
| 97597 | <1% | 21 | $134.74 | |
| 87340 | <1% | 410 | $130.43 | |
| 86038 | <1% | 116 | $121.96 | |
| 84466 | <1% | 581 | $106.52 | |
| 93017 | <1% | 14 | $89.60 | |
| 73590 | <1% | 13 | $77.22 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 154 | $74.05 |
| 84100 | <1% | 177 | $61.45 | |
| 86431 | <1% | 41 | $52.05 | |
| 82140 | <1% | 78 | $49.54 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 427 | $46.62 |
| 88304 | <1% | 33 | $39.47 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 280 | $35.35 |
| 82274 | <1% | 15 | $27.41 | |
| 86787 | <1% | 62 | $23.05 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 739 | $17.66 |
| 86762 | <1% | 45 | $17.25 | |
| 85652 | <1% | 108 | $11.60 | |
| 85007 | <1% | 50 | $10.53 | |
| 83525 | <1% | 15 | $7.68 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 166 | $6.05 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 165 | $5.32 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 34 | $0.00 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 78 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 282 | $0.00 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 0% | 38 | $0.00 |
| 97116 | 0% | 30 | $0.00 | |
| 80179 | 0% | 77 | $0.00 | |
| 88313 | 0% | 20 | $0.00 | |
| 80143 | 0% | 14 | $0.00 | |
| 84145 | 0% | 78 | $0.00 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 0% | 128 | $0.00 |
| 99152 | 0% | 28 | $0.00 | |
| 83516 | 0% | 19 | $0.00 | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 0% | 15 | $0.00 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 0% | 45 | $0.00 |
| 85347 | 0% | 25 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 214 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 20 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 24 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 55 | $0.00 |
| 85379 | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDUNKEL, JASON (CEO)
| Provider | Location | Paid |
|---|---|---|
| Adventist Health System-Sunbelt INC | Wauchula, FL | $7.54M |
| Adventist Health System-Sunbelt INC | Wauchula, FL | $345K |
| Adventist Health System-Sunbelt INC | Avon Park, FL | $235K |
| Adventist Health System-Sunbelt INC | Frostproof, FL | $21K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.